Chronicle Journal: Finance

GeoVax to Present at 2021 BIO Digital

GeoVax Chairman & CEO to Participate in Vaccine Panel Discussion

Atlanta, GA - (NewMediaWire) - June 07, 2021 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 and June 14-18, 2021.  

 

David Dodd, Chairman & CEO, will present an overview of GeoVax’s immunotherapy and vaccine research and development efforts.  The presentation will focus on the Company’s ongoing efforts towards the development of a COVID-19 vaccine capable of addressing the increasing number of SARS-CoV-2 variants.  Mr. Dodd will also discuss the Company’s cancer immunotherapy program and its other vaccine development programs.  The presentation will be available to registered attendees at 9:00am ET June 10.

Attendees at BIO Digital will be able to view GeoVax’s company presentation before live meetings in the BIO One-on-One Partnering™ system begin on June 14.  To meet with GeoVax at BIO Digital, registration information can be found here.

GeoVax Chairman and CEO, David Dodd, will also participate in a panel discussion entitled, “Vaccine Business – Five Minutes of Fame or Five-Time Oscar Winner?”  The panel discussion and live Q&A chat is scheduled for Tuesday, June 15, at 11:05am ET.

About GeoVax

GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer. GeoVax’s current development programs are focused on preventive vaccines against COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa, Marburg and Sudan), HIV and malaria, as well as therapeutic vaccines against multiple cancers. 

Through the Company’s novel Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine. The production of VLPs in vivo mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. 

About BIO

BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

GeoVax Labs, Inc.

678-384-7220

investor@geovax.com

 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.